Treatment of Pleural Effusion

Enables pleural effusion to be managed.

All cancers affecting the thorax lead to an indication of pleurodesis, as does cardiac, renal and liver failure. Our discovery will enable pleural effusion to be managed.

 

Company Name

Oxford University Innovation

Reference Number 1211

Market Sectors:

Bio / Life Sciences, Health, Medical

Operational Areas

Patient Healthcare
 

Commercial Solutions

Improve Customer Care
Increase Efficiency
 

Commercial Opportunities

Seeking Alliance, IP Advice

Speed to Market

Immediate
 

OVERVIEW OF FEATURES, BENEFITS AND RESULTS

Lipoteichoic acid-T, a novel agent, has been shown to produce controlled pleural inflammation/fibrosis for performing pleurodesis. Pleurodesis is the induced adherence of the pleural membranes to control the recurrent collections of liquid or air in the pleural cavity that lead to lung collapse, impaired lung function, and disabling breathlessness. All cancers affecting the thorax lead to an indication of pleurodesis, as does cardiac, renal and liver failure, and certain inflammatory diseases. Our discovery will enable pleural effusion to be managed. The invention allows treatment with good efficacy and minimal side effects.

Special Features:

  • Unmet need. Sterile, medical grade talc poudrage has been used for pleurodesis but is often associated with severe side effects and pain. This leaves a clear unmet clinical need for a new, non-toxic, pleurodesis agent developed through proper clinical trials to meet acceptable regulatory standards.
  • Proven technology. In the invention, a purified bacterial cell wall moiety (lipoteichoic acid-T) has been used to produce pleurodesis. With the agent having completed a phase 1/2a clinical trial, an effective therapeutic dose associated with minimal adverse events has been identified.
  • Great market potential. More than 500,000 patients currently receive the pleurodesis procedure each year in the USA and Europe. This can be expected to increase markedly with a lowered side effect profile.

Applications:

  • About 300,000 new cases of malignant pleural effusion arise in the UK and USA each year, translating to one new case per 1,000 population (increasing in ageing populations).
  • In addition to this, the incidence of air in the pleural space (pneumothorax) is estimated at 18/100,000 per year for men and 6/100,000 per year for women. 25 percent of these patients require pleurodesis.

 

Please confirm you wish to exchange contact information with the innovator of Treatment of Pleural Effusion.

You currently have 0 company connections available this month.

Confirm